Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. by Nicolau, José C et al.
QUA L I T Y AND OU T COME S
Diabetes association with self-reported health, resource
utilization, and prognosis post-myocardial infarction
José C. Nicolau1 | David Brieger2 | Ruth Owen3 | Remo H.M. Furtado1,4 |
Shaun G. Goodman5 | Mauricio G. Cohen6 | Tabassome Simon7,8 |
Dirk Westermann9,10 | Christopher B. Granger11 | Richard Grieve3 |
Satoshi Yasuda12 | Jiyan Chen13 | Katarina Hedman14 | Carl Mellström14 |
Gunnar Brandrup-Wognsen14 | Stuart J. Pocock3
1Instituto do Coraç~ao (InCor), Hospital das Clinicas da Faculdade de Medicina, Universidade de S~ao Paulo, S~ao Paulo, Brazil
2Concord Hospital and University of Sydney, Sydney, Australia
3London School of Hygiene and Tropical Medicine, London, UK
4Hospital Israelita Albert Einstein, S~ao Paulo, Brazil
5Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, Toronto, Canada
6University of Miami Miller School of Medicine, Miami, Florida
7Department of Clinical Pharmacology and Clinical Research Platform of East of Paris, Assistance Publique-Hopitaux de Paris (APHP), Paris, France
8Sorbonne-Université (UPMC-Paris 06), Paris, France
9Department of General and Interventional Cardiology, University Heart Center Eppendorf, Hamburg, Germany
10German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany
11Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
12Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
13Guangdong General Hospital, Provincial Key Laboratory of Coronary Disease, Guangzhou, China
14AstraZeneca, Gothenburg, Sweden
Correspondence
José C. Nicolau, MD, PhD, Instituto do
Coracao (InCor), Hospital das Clínicas
HCFMUSP, Faculdade de Medicina
Universidade de Sao Paulo, Enéas Carvalho
Aguiar, 44, Sao Paulo, SP 05403-000, Brazil.
Email: jose.nicolau@incor.usp.br
Funding information
AstraZeneca; Cactus Life Sciences
Abstract
Background: Diabetes mellitus (DM) is associated with increased cardiovascular
(CV) risk. We compared health-related quality of life (HRQoL), healthcare resource
utilization (HRU), and clinical outcomes of stable post-myocardial infarction
(MI) patients with and without DM.
Hypothesis: In post-MI patients, DM is associated with worse HRQoL, increased
HRU, and worse clinical outcomes.
Methods: The prospective, observational long-term risk, clinical management, and
healthcare Resource utilization of stable coronary artery disease study obtained data
from 8968 patients aged ≥50 years 1 to 3 years post-MI (369 centers; 25 countries).
Patients with ≥1 of the following risk factors were included: age ≥65 years, history of
a second MI >1 year before enrollment, multivessel coronary artery disease, creati-
nine clearance ≥15 and <60 mL/min, and DM treated with medication. Self-reported
Received: 24 June 2020 Revised: 17 September 2020 Accepted: 24 September 2020
DOI: 10.1002/clc.23476
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
1352 Clin Cardiol. 2020;43:1352–1361.wileyonlinelibrary.com/journal/clc
health status was assessed at baseline, 1 and 2 years and converted to EQ-5D scores.
The main outcome measures were baseline HRQoL and HRU during follow-up.
Results: DM at enrollment was 33% (2959 patients, 869 insulin treated). Mean base-
line EQ-5D score (0.86 vs 0.82; P < .0001) was higher; mean number of hospitaliza-
tions (0.38 vs 0.50, P < .0001) and mean length of stay (LoS; 9.3 vs 11.5; P = .001)
were lower in patients without vs with DM. All-cause death and the composite of CV
death, MI, and stroke were significantly higher in DM patients, with adjusted 2-year
rate ratios of 1.43 (P < .01) and 1.55 (P < .001), respectively.
Conclusions: Stable post-MI patients with DM (especially insulin treated) had poorer
EQ-5D scores, higher hospitalization rates and LoS, and worse clinical outcomes vs
those without DM. Strategies focusing specifically on this high-risk population should
be developed to improve outcomes.
Trial registration: ClinicalTrials.gov: NCT01866904 (https://clinicaltrials.gov).
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1 | INTRODUCTION
Diabetes mellitus (DM) is a major global epidemic, with a projected
640 million individuals being affected by this disease by 2040.1 More-
over, heart disease, including acute myocardial infarction (MI), is not
only the leading cause of death but also the leading cause of lost
disability-adjusted life years worldwide. DM is a major factor contrib-
uting to this burden of cardiovascular (CV) disease.2
It is well established that DM is independently and strongly asso-
ciated with CV risk.3,4 In addition, patients with prior MI who also
have DM comprise an important group at a heightened risk of major
adverse CV events (MACE), including hospitalizations for heart failure
(HF) and all-cause mortality.5-7 These associations are even more
important given the fact that, even with contemporary standard of
care, patients with DM and prior MI have a reduced risk of MACE
with prolonged dual antiplatelet therapy,8 high-intensity lipid-lowering
therapy,9,10 and newer antihyperglycemic drugs with proven CV out-
come benefits.11
While the impact of DM in terms of “hard” clinical outcomes, such
as recurrent MI, stroke, and CV mortality, is recognized, very little is
known regarding its association with patient-reported outcomes, such
as health-related quality of life (HRQoL) and healthcare resource utili-
zation (HRU).
Several studies have demonstrated that DM may have a consider-
able negative impact on HRQoL in patients suffering from acute coro-
nary syndrome (ACS),12-16 with one report showing no association.17
However, these studies had limitations such as small sample size,
short-term follow-up, or being restricted to a single country.
Data regarding the potential impact of DM on HRU in the long-
term after MI are even more scarce. Janzon et al demonstrated that
patients deemed to be at high risk after MI contributed to a
substantial burden on HRU.18 Considering that DM is highly associ-
ated with recurrent hospitalizations due to recurrent ischemic MACE
and HF,5,6 its potential impact on HRU in a stable post-MI population
is of major interest.
Therefore, we sought to contribute to a better understanding of
these issues in patients with DM in the TIGRIS (long-Term rIsk, clinical
manaGement, and healthcare Resource utilization of stable coronary
artery dISease) registry, which includes a unique international popula-
tion with MI 1 to 3 years prior to enrollment.
2 | METHODS
2.1 | Study design
TIGRIS was a prospective, observational study that included 9208
patients from 25 countries in Asia-Pacific/Australia, Europe, North
America, and South America. The main objective was to better under-
stand the long-term outcomes and associated HRU in stable individ-
uals with MI 1 to 3 years prior to study enrollment. A list of principal
investigators for the TIGRIS study is provided in Table S1.
TIGRIS (ClinicalTrials.gov, NCT01866904) enrollment criteria as
well as patient characteristics and treatment patterns have been publi-
shed previously.19,20 The TIGRIS study was performed in accordance
with ethical principles that are consistent with the Declaration of Hel-
sinki, the International Council for Harmonization Good Clinical Prac-
tice guidelines, and applicable legislation on nonintervention studies.
All participants provided written informed consent. The study proto-
col and informed consent were reviewed by the corresponding health
authorities and ethics boards of all participating study sites. This
includes Human Genome Research (HGR) approval in China to include
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750 Chinese patients. Patients and the public were not involved in
the research process. Briefly, we included patients aged ≥50 years
with a documented history of prior MI and at least one of the follow-
ing risk factors: age ≥65 years, documented history of a second MI
>1 year prior to study enrollment, multivessel coronary artery disease,
creatinine clearance ≥15 and <60 mL/min, and DM treated with medi-
cation. Main exclusion criteria were any condition or circumstance
that could limit the complete follow-up of the patient (eg, end-stage
disease with a life expectancy of <1 year, psychiatric disturbances,
alcohol or drug abuse); current participation in a blinded, randomized
controlled trial; and treatment with ticagrelor beyond 12 months after
MI or off-label use of ticagrelor.
Data were collected during the initial visit and every 6 months
thereafter for 24 months by telephone or in person. The EuroQol
Research Foundation survey instrument for measuring self-reported
health status in 5 dimensions (EQ-5D; mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression) with three levels of
severity (EQ-5D-3L; none, moderate, and severe) was completed by
every individual at each visit.21,22
A standardized electronic case report form was used for data col-
lection, which included medical history, demographics, variables from
routine examination (at baseline), medication use, HRU, and clinical
events (ischemic and hemorrhagic), during follow-up.
In the present study, 8968 patients (97.2% of the total popula-
tion) with complete data on DM status were analyzed. Data on self-
reported health status were available in 7260 patients, and data on
HRU were available in 7838 patients. The main focus of this study
was HRQoL at baseline and HRU during follow-up.
2.2 | Statistical analysis
Comparisons of patient characteristics by DM status were summa-
rized by mean and SD for quantitative variables and by frequency/
percentage for categorical variables. P-values were based on a
2-sample t-test, χ2 test, and test for trend for quantitative, binary, and
ordinal variables, respectively.
For the EQ-5D-3L self-reported health questionnaire, the United
Kingdom (UK)-weighted index has been used as the most widely
accepted summary of overall health status.23 This combines the five
domains (mobility, self-care, usual activities, pain/discomfort, and
depression/anxiety) into a single score. A score of 1 indicates “no
problems” on all five items, and a score of less than 1 indicates
increasingly poor self-rated health status, down to a rare score of
0 indicating a state rated as “bad as being dead.”
Hospitalizations and other HRU items were based on 6-monthly
patient recall during follow-up at 6, 12, 18, and 24 months after
enrollment. These have been totaled to summarize each patient's
HRU over 24 months of follow-up.
The 2-year percentage incidence of clinical outcomes is reported
by DM status, using Kaplan-Meier estimates to account for patients
lost to follow-up. Poisson regression models were used to adjust for
other baseline influences on risk of event. Variables included in the
adjustment were those in the TIGRIS risk index model,24 which were
age ≥65 years, second prior MI, chronic kidney disease, HF, peripheral
artery disease, CV event in the past 6 months, major bleeding, medical
management of index MI, diuretic use, EQ-5D-weighted index score,
region, and country (as random effects). All analyzes were performed
using STATA version 15.1.
3 | RESULTS
In this population of 8968 patients 1 to 3 years post-MI, 2959 (33%)
had DM, of whom 869 (29%) were treated with insulin (see CON-
SORT diagram; Figure S1). Baseline characteristics of the population
by DM status are described in Table S2. Compared with patients with-
out DM, patients with DM were younger (67.5 vs 65.8 years) and had
a higher body mass index (BMI; 26.9 vs 28.3 kg/m2). Patients with
DM also had a higher prevalence of peripheral artery disease (5.2% vs
9.8%), HF (10.0% vs 14.6%), anemia (2.3% vs 4.1%), angina (8.9% vs
12.2%), and stroke (3.7% vs 5.9%). Moreover, patients with DM also
had higher CV event-related hospitalization rates in the 6 months
prior to enrollment (5.0% vs 6.4%). All these measures were more pro-
nounced in patients with insulin-dependent DM, which comprised
both patients with type 1 (N = 86) and type 2 (N = 783) DM (Table S3).
Table S4 shows the prevalence of DM by region and country. The
highest prevalence of DM was observed in Asia and Australia (37.0%),
followed by Latin America (36.3%). The lowest prevalence was
observed in Europe (29.2%).
Table S5 shows the utilization of evidence-based treatments at
enrollment by DM status. Of note, the use of dual antiplatelet ther-
apy, angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers, and beta-blockers was higher in patients with
DM. Conversely, patients without DM were treated more often with
statins and/or other lipid-lowering drugs.
Table 1 and Figure 1A show the association of DM with self-
reported health status at baseline using the EQ-5D-3L questionnaire.
Patients with DM reported more problems in each domain of the EQ-
5D questionnaire, which resulted in an overall significantly worse
mean EQ-5D UK-weighted index score at enrollment. The mean EQ-
5D visual analog score was also significantly worse in patients with
DM. For all these aspects of EQ-5D, patients with insulin-treated DM
fared worse than patients with noninsulin-treated DM. Table 2 docu-
ments how self-reported health status was poorer in patients with
DM, especially those treated with insulin, and also deteriorated more
over the 2-year follow-up. These associations persisted after adjust-
ment for other patient characteristics and were driven by significantly
poorer scores in each domain of the EQ-5D questionnaire, with the
exception of anxiety/depression in which solely insulin-treated DM
patients fared worse.
In terms of HRU, Table 3 and Figure 1B,C shows the incidence
and duration of all-cause hospitalization in the 2 years following
enrollment. The percentage of patients hospitalized in the group with-
out DM was lower vs that in the group with DM (24.7% vs 29.9%),
with a mean of 0.38 vs 0.50 hospitalizations over the 2-year follow-
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up, respectively. The mean duration of hospitalization was also longer
in patients with DM vs those without DM (9.25 vs 11.53 days).
Table S6 shows the incidence of hospitalizations for CV events and
bleeding events, emergency, and general practitioner visits for CV or
bleeding events, cardiologist visits, and other specialist visits. The
results are consistent with those shown in Table 1, with higher HRU
in those with DM than in those without DM. All these aspects of HRU
(except for cardiologist visits) were more pronounced in patients who
were treated with insulin.
Regarding clinical outcomes, Table S7 shows that DM had signifi-
cant associations with the risk of atherosclerotic events (MI, stroke,
and unstable angina requiring urgent revascularization) and deaths
(both all-cause and CV) but not with major bleeding events.
Figure S2A,C show the cumulative incidence over 2 years for the
composite of CV death, MI, or stroke by DM status; Figure S2B,D
show the cumulative all-cause mortality over 2 years by DM status.
Patients with DM (especially insulin-treated patients) had a signifi-
cantly worse outcome for the composite endpoint and for all its com-
ponents isolated (all-cause mortality, MI, stroke, and unstable angina
with urgent revascularization). Adjusted rate ratios for the composite
of CV death, MI, or stroke were 1.55 (95% confidence interval [CI],
1.27-1.89) for the comparison between DM and non-DM, 1.41 (95%
CI, 1.12-1.78) for the comparison between noninsulin-treated DM
and non-DM, and 1.83 (95% CI, 1.39-2.39) for the comparison
TABLE 1 Self-reported health (EQ-5D) at baseline by diabetes status
No diabetes Diabetes
P-value
Noninsulin-treated diabetes Insulin-treated diabetes
N = 6009 N = 2959 N = 2090 N = 869
EQ-5D UK-weighted index scorea, mean ± SD 0.86 ± 0.20 0.82 ± 0.23 <.0001 0.84 ± 0.21 0.77 ± 0.26
1 3043 ± 50.9 1271 ± 43.2 – 962 ± 46.3 309 ± 35.8
0.75-0.99 1524 ± 25.5 801 ± 27.2 – 581 ± 28.0 220 ± 25.5
0.70-0.74 521 ± 8.7 271 ± 9.2 – 178 ± 8.6 93 ± 10.8
0.65-0.69 337 ± 5.6 200 ± 6.8 – 128 ± 6.2 72 ± 8.3
<0.64 553 ± 9.3 398 ± 13.5 – 229 ± 11.0 169 ± 19.6
EQ-5D visual analog scaleb (0-100), mean ± SD 77.0 ± 16.4 74.2 ± 17.8 <.0001 75.4 ± 17.3 71.5 ± 18.7
>92.5 776 ± 13.0 282 ± 9.6 – 221 ± 10.7 61 ± 7.1
82.5-92.5 1390 ± 23.3 660 ± 22.5 – 476 ± 23.0 184 ± 21.3
72.5-82.5 1786 ± 30.0 844 ± 28.8 – 626 ± 30.3 218 ± 25.3
62.5-72.5 1000 ± 16.8 462 ± 15.8 – 312 ± 15.1 150 ± 17.4
52.5-62.5 445 ± 7.5 278 ± 9.5 – 186 ± 9.0 92 ± 10.7
42.5-52.5 360 ± 6.0 239 ± 8.2 – 150 ± 7.2 89 ± 10.3
0-42.5 201 ± 3.4 166 ± 5.7 – 98 ± 4.7 68 ± 7.9
EQ-5D mobility – – – – –
Some problems 1303 (21.8) 877 (29.8) <.0001 551 (26.5) 326 (37.8)
Severe problems 7 (0.1) 7 (0.2) – 4 (0.2) 3 (0.3)
EQ-5D self-care – – – – –
Some problems 269 (4.5) 206 (7.0) <.0001 117 (5.6) 89 (10.3)
Severe problems 22 (0.4) 17 (0.6) – 8 (0.4) 9 (1.0)
EQ-5D usual activities – – – – –
Some problems 962 (16.1) 579 (19.7) <.0001 369 (17.8) 210 (24.3)
Severe problems 45 (0.8) 56 (1.9) – 26 (1.3) 30 (3.5)
EQ-5D pain/discomfort – – – – –
Some problems 1899 (31.8) 1059 (36.0) <.0001 713 (34.3) 346 (40.1)
Severe problems 138 (2.3) 105 (3.6) – 53 (2.5) 52 (6.0)
EQ-5D depression/anxiety – – – – –
Some problems 1222 (20.4) 647 (22.0) .008 418 (20.1) 229 (26.5)
Severe problems 91 (1.5) 66 (2.2) – 42 (2.0) 24 (2.8)
Note: Summary statistics are presented as n (%) unless otherwise stated. For both the scales, higher scores indicate better self-rated health status.
Abbreviations: EQ-5D, EuroQol Research Foundation survey instrument for measuring self-reported health status in 5 dimensions; UK, United Kingdom.
aFor the EQ-5D UK-weighted index, a score of 1 indicates no problems for mobility, self-care, usual activities, pain/discomfort, or depression/anxiety,
whereas a score of 0 indicates a state as bad as death.
bFor the EQ-5D visual analog scale, a score of 100 indicates “best health you can imagine,” while a score of 0 indicates “worst health you can imagine.”
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between insulin-treated DM and non-DM (Table 4). For all-cause
death, the corresponding rate ratios were 1.43 (95% CI, 1.13-1.82),
1.31 (95% CI, 0.99-1.72), and 1.66 (95% CI, 1.21-2.28), respectively.
4 | DISCUSSION
In our study, patients with DM and prior MI 1 to 3 years before enroll-
ment were at a heightened risk of both MACE and all-cause mortality
compared with patients with prior MI and no DM. Moreover, there
was a gradient in risk when patients with DM were analyzed
according to insulin status, such that being on insulin was associated
with an even higher risk for CV events. Patients with DM were also
more frequently hospitalized and had more HRU, as expressed by the
higher number of hospitalizations, emergency department visits, and
outpatient visits. Finally, our study demonstrates that patient-
reported HRQoL, as measured by the EQ-5D, was significantly associ-
ated with the presence of DM in those with prior MI.
Previous reports have suggested that patients with DM and no
prior MI have the same risk of coronary death as patients with prior
MI and no DM.25 Patients with both DM and prior MI comprised a
subgroup of particularly high-risk patients, with deaths due to coro-
nary disease approaching 50% at 7 years.25 In the REACH registry,
among patients with or at high risk for atherothrombotic CV disease,
the presence of DM was associated with a nearly 50% increase in the
risk of MACE, CV mortality, and all-cause mortality during a 4-year
follow-up.5 Comparable findings were published in a subanalysis from
the PEGASUS-TIMI 54 trial, a randomized study enrolling post-MI
patients whose inclusion criteria were similar to those in the TIGRIS
registry. In PEGASUS-TIMI 54, patients with DM also had an approxi-
mately 1.5-fold increase in both MACE and all-cause mortality com-
pared with those without DM. Similar to our findings, there were also
numerically higher rates of MACE and CV death in patients receiving
insulin.8
DM is not only associated with incident CV disease and overall
mortality but also negatively impacts HRQoL. In post-ACS patients
from the Veterans Health Administration, Rumsfeld et al demon-
strated that DM had a negative impact on HRQoL that was compara-
ble to the impact observed in depression and similar to the estimated
HRQoL in other chronic diseases, such as HF, chronic obstructive pul-
monary disease, and stroke.12 A publication examining long-term MI
survivors from the MONICA/KORA registry in Germany demon-
strated that DM had a worse impact on EQ-5D than either
age ≥75 years or a history of more than one MI.15 Similarly, Shah et al
showed that in patients with stable coronary artery disease (most of
whom had a history of ACS), DM negatively affected all domains of
the EQ-5D, except self-care.26 In contrast, a Canadian registry
F IGURE 1 Legend on next coloumn.
F IGURE 1 Quality of life and healthcare utilization. A, Quality of
life. B, Hospitalizations. C, Hospital stay. Abbreviations: CI, confidence
interval; EQ-5D, EuroQol Research Foundation survey instrument for
measuring self-reported health status in 5 dimensions
1356 NICOLAU ET AL.
TABLE 2 Association of diabetes (overall and by insulin treatment) with self-reported health status at baseline and change in self-reported
health status over 2 years' follow-up
Mean EQ-5D UK-weighted index score at baseline (N = 8919)
Crude effecta (95% CI) P-value Adjusted effecta,b (95% CI) P-value
Diabetes −0.038 (−0.047 to −0.029) <.0001c −0.030 (−0.039 to −0.021) <.0001c
Noninsulin-treated diabetes −0.018 (−0.028 to −0.007)
<.0001d
−0.013 (−0.023 to −0.003)
<.0001d
Insulin-treated diabetes −0.087 (−0.102 to −0.072) −0.073 (−0.087 to −0.058)
EQ-5D domains at baseline
Crude ORe (95% CI) P-value Adjusted ORb,e (95% CI) P-value
Mobility
Diabetes 1.53 (1.39-1.69) <.0001c 1.55 (1.39-1.73) <.0001c




Insulin-treated diabetes 2.20 (1.89-2.56) 2.23 (1.89-2.63)
Self-care
Diabetes 1.60 (1.34-1.92) <.0001c 1.53 (1.26-1.85) <.0001c




Insulin-treated diabetes 2.51 (1.97-3.19) 2.34 (1.80-3.04)
Usual activities
Diabetes 1.37 (1.23-1.53) <.0001c 1.37 (1.22-1.55) <.0001c




Insulin-treated diabetes 1.95 (1.66-2.30) 1.90 (1.59-2.27)
Pain/discomfort
Diabetes 1.28 (1.17-1.40) <.0001c 1.25 (1.14-1.38) <.0001c




Insulin-treated diabetes 1.72 (1.49-1.99) 1.61 (1.38-1.88)
Anxiety/depression
Diabetes 1.14 (1.03-1.27) .01c 1.03 (0.92-1.15) .65c




Insulin-treated diabetes 1.48 (1.27-1.74) 1.35 (1.14-1.60)
Mean change in EQ-5D-weighted index score over 2 years (N = 7260)
Crude effectf (95% CI) P-value Adjusted effectb (95% CI) P-value
Diabetes −0.017 (−0.026 to −0.008) .0003a −0.016 (−0.025 to −0.007) .0005a
Noninsulin-treated diabetes −0.008 (−0.018 to 0.002)
<.0001d
−0.008 (−0.018 to 0.002)
<.0001d
Insulin-treated diabetes −0.040 (−0.055 to −0.025) −0.038 (−0.052 to −0.023)
Change in EQ-5D domains over 2 years
Crude ORg (95% CI) P-value Adjusted ORb,g (95% CI) P-value
Mobility
Diabetes 1.27 (1.12-1.44) .0002c 1.34 (1.17-1.54) <.0001c




Insulin-treated diabetes 1.69 (1.39-2.05) 1.83 (1.47-2.27)
Self-care
Diabetes 1.48 (1.18-1.84) .0005c 1.54 (1.22-1.94) .0002c




Insulin-treated diabetes 1.91 (1.39-2.63) 1.99 (1.42-2.79)
Usual activities
Diabetes 1.35 (1.17-1.57) <.0001c 1.35 (1.16-1.58) .0002c




Insulin-treated diabetes 1.94 (1.56-2.41) 1.96 (1.55-2.48)
(Continues)
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assessing HRQoL up to 1 year after MI found a positive association
between DM and HRQoL scores measured by the 36-item Short Form
(SF-36) questionnaire. The authors do acknowledge that this unex-
pected finding could be ascribed to uncontrolled confounders render-
ing a spurious association or to the fact that subjects lost to follow-up
in that cohort were more likely to have DM.17 These previous reports
enrolled patients from single countries. Considering reports including
patients from different global regions, a subanalysis from the random-
ized MERLIN trial also found that DM was associated with lower
HRQoL scores in serial measurements for 1 year after ACS.14 In a sub-
analysis from the PLATO trial, DM was also independently associated
with a worse HRQoL at 1 year after ACS, with parameter estimates
comparable to those observed in patients having a prior MI.16 In con-
trast to these two reports, in the TIGRIS registry, patients had experi-
enced their last MI more than 1 year ago; therefore, the HRQoL could
be assessed more remotely from the acute event. In addition, owing
to less stringent inclusion criteria than those required for randomized
clinical trials, TIGRIS enrolled a population more representative of
TABLE 2 (Continued)
Mean EQ-5D UK-weighted index score at baseline (N = 8919)
Crude effecta (95% CI) P-value Adjusted effecta,b (95% CI) P-value
Pain/discomfort
Diabetes 1.19 (1.07-1.33) .002c 1.18 (1.05-1.33) .006c




Insulin-treated diabetes 1.51 (1.27-1.80) 1.46 (1.21-1.76)
Anxiety/depression
Diabetes 1.13 (0.99-1.28) .07c 1.04 (0.91-1.20) .54c




Insulin-treated diabetes 1.43 (1.17-1.75) 1.33 (1.07-1.65)
Abbreviations: ANCOVA, analysis of covariance; BMI, body mass index; CI, confidence interval; EQ-5D, EuroQol Research Foundation survey instrument
for measuring self-reported health status in 5 dimensions; OR, odds ratio; UK, United Kingdom.
aMean effects are for each diabetes group vs non-diabetes group. Adjusted mean effects use a linear regression model adjusted for age, sex, region, BMI,
years in education, and smoking status as fixed effects and country as a random effect.
bAdjusted for age, sex, region, BMI, years in education, smoking status, and baseline EQ-5D-weighted index score as fixed effects and country as a random
effect.
cComparison between diabetes vs no diabetes.
dGlobal test for no association with diabetes group (no diabetes, noninsulin-treated diabetes, and insulin-treated diabetes).
eORs were estimated using ordinal polytomous regression models and the odds of having moderate/severe problems were compared to the odds of having
no problems or the odds of having severe problems to the odds of having no/moderate problems in each respective domain.
fAdjusted for EQ-5D-weighted index score using ANCOVA.
gORs were estimated using ordinal polytomous regression models and the odds of having improved were compared to the odds of having no change/wors-
ened over 2 years' follow-up or the odds of having no change/improved to the odds of having worsened over 2 years' follow-up in each respective
domain.
TABLE 3 Hospitalizations for any cause during 2-year follow-up by diabetes statusa




N = 5249 N = 2589 N = 1866 N = 723
Mean number of hospitalizations (95%
CI)
0.38 (0.35-0.40) 0.50 (0.46-0.53) – 0.44 (0.40-0.49) 0.63 (0.55-0.71)
Number of hospitalizations, n (%) – – <.0001 – –
0 3951 (75.3) 1817 (70.2) – 1354 (72.5) 464 (64.2)
1 889 (16.9) 486 (18.8) – 339 (18.2) 147 (20.3)
2 259 (4.9) 158 (6.1) – 98 (5.3) 60 (8.3)
3 93 (1.8) 79 (3.1) – 44 (2.4) 35 (4.8)
4+ 57 (1.1) 49 (1.9) – 32 (1.7) 17 (2.4)






.001 10.95 (9.71-12.19) 12.67 (10.22-15.13)
Abbreviation: CI, confidence interval.
aAmong 7838 patients with available healthcare utilization data at every visit.
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routine clinical practice in different economic and ethnic regions.
Finally, it is important to note that some comorbidities that more
often presented in the DM group may have influenced some of the
EQ-5D parameters. For example, obesity was more common in the
DM group, which could have influenced mobility, usual activities, and
pain. In addition, psychiatric diagnoses (including depression) were
common among patients with diabetes and were related to a worse
prognosis.27
Regarding HRU, few reports have explored this topic with high
granularity in outpatients after MI. In a database derived from the
United States health plans, employers, and government organizations,
Menzin et al found that 21% of patients after ACS were hospitalized
after 1 year and health-related expenditures were mostly driven by
hospitalizations. The presence of comorbidities (DM being the most
common) was independently associated with a 50% increase in hospi-
talization.28 In a Swedish registry of post-MI patients followed
through a median of 6 years after the index event, Janzon et al dem-
onstrated a marked increase in healthcare costs in the first year after
MI. Subsequently, the costs remained consistent from the second year
onward; those costs were mostly related to hospitalizations rather
than medications and other healthcare resources. After the first year,
in parallel with the population from our registry, there appeared to be
an association of higher costs with the number of higher risk features
(including DM).18 However, data regarding an association of costs and
DM separately were not available in these two reports. In a cost-
effectiveness analysis from the TRITON-TIMI 38 trial, in patients
followed for up to 15 months after ACS treated with percutaneous
coronary intervention for the index event, patients with DM had
numerically higher costs compared with those without DM.29 Simi-
larly, in a subanalysis from the PLATO trial, higher costs were associ-
ated with DM.30 Although we did not analyze direct costs, we
assessed HRU in more detail than in prior studies. We have
demonstrated that DM was associated with higher incidences of hos-
pitalizations both in the 6 months prior to inclusion in the trial and in
the 24 months of follow-up, suggesting that DM contributes to a
higher baseline cost use of hospital clinical resources, as well as exac-
erbating CV cost. Our results reinforce the recommendations of the
WHO31 in terms of the importance of diet, physical activity, tobacco
cessation, and lowering the levels of glucose and other known risk
factors for atherosclerosis.
Our study has some limitations. First, although clinical endpoints
were verified in medical records, they were not centrally adjudicated
in the TIGRIS registry. It is reassuring that the increased risk of MACE
and other clinically relevant events in patients with DM in the TIGRIS
registry was consistent with that observed in the PEGASUS-TIMI
54 trial, where all events were centrally adjudicated by a clinical
events committee.8 Second, we ascertained HRQoL with only one
type of instrument, the EQ-5D. It should be mentioned that this ques-
tionnaire is widely used in HRQoL assessment outcome studies and
has been validated in post-MI patients; therefore, it is unlikely that
results would be different should another instrument have been
used.32 Third, we did not consider costs in our analysis of HRU. How-
ever, given that this is a global study across different types of
healthcare systems and payers, it would be difficult to standardize
costs in a meaningful manner. Considering that from similar publica-
tions the costs from hospitalizations dominate the health expenditures
after MI,18 we believe our finding of an increase in hospitalizations
(and length of stay[LoS]) and emergency visits among patients with
DM is an adequate surrogate for healthcare-related expenses. Fourth,
owing to the specific inclusion criteria for the registry, DM, more than
one prior MI, and renal dysfunction were enrichment risk factors. It is
possible that this would affect the association of DM and risk factors,
and our findings may not all be applicable to a lower risk post-MI pop-
ulation. Finally, as with any observational study, we cannot establish a
TABLE 4 Association of diabetes (overall and by insulin treatment) with the risk of CV death, MI, and stroke and the risk of all-cause death
over 2-year follow-up
Crude RR (95% CI) P-value Adjusted RR (95% CI) P-value
CV death, MI, and stroke
Diabetes 1.85 (1.53-2.25) <.0001a 1.55 (1.27-1.89) <.0001a
Noninsulin-treated diabetes 1.51 (1.21-1.90) <.0001b 1.41 (1.12-1.78) <.0001b
Insulin-treated diabetes 2.70 (2.09-3.48) 1.83 (1.39-2.39)
All-cause death
Diabetes 1.84 (1.46-2.32) <.0001a 1.43 (1.13-1.82)a .003
Noninsulin-treated diabetes 1.45 (1.10-1.90) <.0001b 1.31 (0.99-1.72) .001b
Insulin-treated diabetes 2.81 (2.09-3.78) 1.66 (1.22-2.28)
Note: Results are from the Poisson regression model investigating the crude and adjusted association of diabetes with the rate of the composite outcome
of CV death, MI, and stroke and the rate of all-cause death, adjusted for variables in the TIGRIS risk index model: age ≥65 years, second prior MI, chronic
kidney disease, heart failure, peripheral artery disease, CV event in the past 6 months, major bleed, medical management of index MI, diuretics, EQ-5D-
weighted index score, region, and country as random effects.
Abbreviations: CI, confidence interval; CV, cardiovascular; EQ-5D, EuroQol Research Foundation survey instrument for measuring self-reported health sta-
tus in 5 dimensions; MI, myocardial infarction; RR, rate ratio; TIGRIS, long-Term rIsk, clinical manaGement and healthcare Resource utilization of stable cor-
onary artery dISease.
aComparison between diabetes vs no diabetes.
bGlobal test for no association with diabetes group (no diabetes, noninsulin-treated diabetes, and insulin-treated diabetes).
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definitive causal relationship, since the results could be related to
unmeasured confounders.
5 | CONCLUSIONS
In stable outpatients' post-MI, the presence of DM is associated with
decreased long-term survival and an increased risk for ischemic
events. In addition, DM is associated with a higher HRU and worse
HRQoL. These results could help inform healthcare system planning
internationally in view of the global DM pandemic.
ACKNOWLEDGMENTS
Editorial support was provided by Cactus Life Sciences (part of Cactus
Communications) and funded by AstraZeneca. The long-Term rIsk,
clinical manaGement, and healthcare Resource utilization of stable
coronary artery dISease (TIGRIS) study is sponsored by AstraZeneca
AB, Södertälje, Sweden. The sponsor contributed to the study con-
ception and design and commented on the analyses.
José C. Nicolau has received speaker/consulting honoraria and/or
research grant support from Amgen, AstraZeneca, Bayer, BMS,
Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Pfizer, and
Sanofi. David Brieger has received speaker/consulting honoraria
and/or research grant support from Amgen, AstraZeneca, Bayer,
Boehringer Ingelheim, BMS, Eli Lilly, Merck, and Sanofi. Ruth Owen
and Stuart J. Pocock have received research grant support from
AstraZeneca. Remo H.M. Furtado reports grants and personal fees
from AstraZeneca, personal fees from Servier, and grants from EMS,
Pfizer, Novo Nordisk, DalCor, Novartis, and Jansen, all of these were
outside of the submitted work. Shaun G. Goodman has received
speaker/consulting honoraria and/or research grant support from
Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, CSL Behring,
Daiichi Sankyo, Eli Lilly, Fenix Group International, Ferring Pharma-
ceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson &
Johnson, Luitpold Pharmaceuticals, Matrizyme, Merck, Novartis, Novo
Nordisk, Pfizer, Regeneron, Sanofi, Servier, and Tenax Pharmaceuti-
cals. Mauricio G. Cohen has received speaker/consulting honoraria
and/or research grant support from AstraZeneca, Medtronic,
Abiomed, and Merit Medical. Tabassome Simon has received speaker/
consulting honoraria and/or research grant support from Astellas,
Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly,
GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Dirk Wes-
termann has received speaker/consulting honoraria and/or research
grant support from AstraZeneca, Bayer, Berlin-Chemie, Biotronik, and
Novartis. Christopher B.Granger has received consulting honoraria
and/or research grant support from Armetheon, AstraZeneca, Bayer,
Boehringer Ingelheim, BMS, Daiichi Sankyo, Eli Lilly, Gilead,
GlaxoSmithKline, Hoffmann-La Roche, Janssen, Metronic, Pfizer, Salix
Pharmaceuticals, Sanofi, Takeda, and The Medicines Company. Rich-
ard Grieve has nothing to disclose. Satoshi Yasuda has received
speaker/consulting honoraria and/or research grant support from
Takeda, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, and BMS.
Jiyan Chen has received research grant support from AstraZeneca and
consulting honoraria from MicroPort, APT Medical, and JW Medical.
Katarina Hedman, Carl Mellström, and Gunnar Brandrup-Wognsen
are employees of AstraZeneca.
AUTHOR CONTRIBUTIONS
José C. Nicolau, conception and design, analysis and interpretation of
data, and drafting and writing the final version of the manuscript; Stu-
art J. Pocock and Ruth Owen, data analysis and interpretation and
drafting and revision of the manuscript; Remo H.M. Furtado, data
analysis and revision of the manuscript; David Brieger, Shaun
G. Goodman, Mauricio G. Cohen, Tabassome Simon, Dirk Wes-
termann, Christopher B. Granger, Richard Grieve, Satoshi Yasuda,
Jiyan Chen, Katarina Hedman, Carl Mellström, and Gunnar Brandrup-
Wognsen, conduct of the registry and revision of the manuscript.
DATA AVAILABILITY STATEMENT
Data underlying the findings described in this manuscript may be




José C. Nicolau https://orcid.org/0000-0002-9680-3689
David Brieger https://orcid.org/0000-0001-6115-0326
Dirk Westermann https://orcid.org/0000-0002-7542-1956
Stuart J. Pocock https://orcid.org/0000-0003-2212-4007
REFERENCES
1. Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V. Type 2 diabetes:
demystifying the global epidemic. Diabetes. 2017;66:1432-1442.
2. GBD 2016 DALYs and HALE Collaborators. Global, regional, and
national disability-adjusted life-years (DALYs) for 333 diseases and
injuries and healthy life expectancy (HALE) for 195 countries and ter-
ritories, 1990–2016: a systematic analysis for the Global Burden of
Disease Study 2016. Lancet. 2017;390:1260-1344.
3. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes
mellitus, fasting blood glucose concentration, and risk of vascular dis-
ease: a collaborative meta-analysis of 102 prospective studies. Lancet.
2010;375:2215-2222.
4. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascu-
lar disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:
1407-1418.
5. Cavender MA, Steg PG, Smith SC Jr, et al. Impact of diabetes
mellitus on hospitalization for heart failure, cardiovascular events,
and death: outcomes at 4 years from the Reduction of
Atherothrombosis for Continued Health (REACH) registry. Circula-
tion. 2015;132:923-931.
6. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of
4-year cardiovascular event rates in stable outpatients at risk of or
with atherothrombosis. JAMA. 2010;304:1350-1357.
7. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality
following acute coronary syndromes. JAMA. 2007;298:765-775.
8. Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in ischemic events
with ticagrelor in diabetic patients with prior myocardial infarction in
PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67:2732-2740.
9. Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding
ezetimibe to statin therapy on cardiovascular outcomes and safety in
patients with versus without diabetes mellitus: results from
1360 NICOLAU ET AL.
IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy
International Trial). Circulation. 2018;137:1571-1582.
10. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and
efficacy of the PCSK9 inhibitor evolocumab in patients with and
without diabetes and the effect of evolocumab on glycaemia and risk
of new-onset diabetes: a prespecified analysis of the FOURIER ran-
domized controlled trial. Lancet Diabetes Endocrinol. 2017;5:941-950.
11. Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and cardiovascu-
lar outcomes in patients with type 2 diabetes mellitus and previous
myocardial infarction. Circulation. 2019;139:2516-2527.
12. Rumsfeld JS, Magid DJ, Plomondon ME, et al. Predictors of quality of
life following acute coronary syndromes. Am J Cardiol. 2001;88:
781-784.
13. Peterson PN, Spertus JA, Magid DJ, et al. The impact of diabetes on
one-year health status outcomes following acute coronary syn-
dromes. BMC Cardiovasc Disord. 2006;6:41.
14. Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on
disease-specific health status and quality of life among patients with
acute coronary syndromes: results from the MERLIN-TIMI 36 ran-
domized trial. Circ Cardiovasc Qual Outcomes. 2008;1:107-115.
15. Schweikert B, Hunger M, Meisinger C, König HH, Gapp O, Holle R.
Quality of life several years after myocardial infarction: comparing
the MONICA/KORA registry to the general population. Eur Heart J.
2009;30:436-443.
16. Levin LÅ, Wallentin L, Bernfort L, et al. Health-related quality of life
of ticagrelor versus clopidogrel in patients with acute coronary
syndromes-results from the PLATO trial. Value Health. 2013;16:
574-580.
17. Beck CA, Joseph L, Bélisle P, Pilote L, QOLAMI Investigators (Quality
of life in acute myocardial infarction). Predictors of quality of life
6 months and 1 year after acute myocardial infarction. Am Heart J.
2001;142:271-279.
18. Janzon M, Henriksson M, Hasvold P, Hjelm H, Thuresson M,
Jernberg T. Long-term resource use patterns and healthcare costs
after myocardial infarction in a clinical practice setting: results from a
contemporary nationwide registry study. Eur Heart J Qual Care Clin
Outcomes. 2016;2:291-298.
19. Westermann D, Goodman SG, Nicolau JC, et al. Rationale and design
of the long-Term rIsk, clinical manaGement, and healthcare Resource
utilization of stable coronary artery dISease in post-myocardial infarc-
tion patients (TIGRIS) study. Clin Cardiol. 2017;40:1197-1204.
20. Goodman SG, Nicolau JC, Requena G, et al. Longer-term oral anti-
platelet use in stable post-myocardial infarction patients: insights
from the long-Term rIsk, clinical manaGement and healthcare
Resource utilization of stable coronary artery dISease (TIGRIS) obser-
vational study. Int J Cardiol. 2017;236:54-60.
21. EuroQol Group. EuroQol–a new facility for the measurement of
health-related quality of life. Health Policy. 1990;16:199-208.
22. Ellis JJ, Eagle KA, Kine-Rogers EM, Erickson SR. Validation of the EQ-
5D in patients with a history of acute coronary syndrome. Curr Med
Res Opin. 2005;21:1209-1216.
23. Dolan P. Modeling valuations for EuroQol health states. Med Care.
1997;35:1095-1108.
24. Pocock SJ, Brieger D, Gregson J, et al. A novel approach to quantify-
ing risk of major cardiovascular events in patients 1-3 years post-
myocardial infarction: insights from the global prospective TIGRIS
registry. J Am Coll Cardiol. 2019;73(9 suppl 1):83.
25. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality
from coronary heart disease in subjects with type 2 diabetes and in
nondiabetic subjects with and without prior myocardial infarction. N
Engl J Med. 1998;339:229-234.
26. Shah B, Deshpande S. Assessment of effect of diabetes on health-
related quality of life in patients with coronary artery disease using
the EQ-5D questionnaire. Value Health Reg Issues. 2014;3:67-72.
27. Wändell P, Ljunggren G, Wahlström L, Carlsson AC. Diabetes and
psychiatric illness in the total population of Stockholm. J Psychosom
Res. 2014;77:169-173.
28. Menzin J, Wygant G, Hauch O, Jackel J, Friedman M. One-year costs
of ischemic heart disease among patients with acute coronary syn-
dromes: findings from a multi-employer claims database. Curr Med
Res Opin. 2008;24:461-468.
29. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of pra-
sugrel versus clopidogrel in patients with acute coronary syndromes
and planned percutaneous coronary intervention: results from the
trial to assess improvement in therapeutic outcomes by optimizing
platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarc-
tion TRITON-TIMI 38. Circulation. 2010;121:71-79.
30. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M, PLATO
Health Economic Substudy Group. Cost-effectiveness of treating
acute coronary syndrome patients with ticagrelor for 12 months:
results from the PLATO study. Eur Heart J. 2013;34:220-228.
31. World Health Organization. Prevention of cardiovascular disease: guide-
lines for assessment and management of total cardiovascular risk.
https://apps.who.int/iris/handle/10665/43685. Accessed June 2, 2020.
32. Nowels D, McGloin J, Westfall JM, Holcomb S. Validation of the EQ-
5D quality of life instrument in patients after myocardial infarction.
Qual Life Res. 2005;14:95-105.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Nicolau JC, Brieger D, Owen R, et al.
Diabetes association with self-reported health, resource
utilization, and prognosis post-myocardial infarction. Clin
Cardiol. 2020;43:1352–1361. https://doi.org/10.1002/clc.
23476
NICOLAU ET AL. 1361
